OXB
NEUTRALOxford Biomedica Announces PDMR Dealings
The biotechnology company has announced a share transaction by one of its non-executive directors.
Oxf Biomedica
570.00GBX
-0.87%
Market Cap
685.03M
Volume
262.04k
149% of avg
P/E Ratio
-22.05
EPS (TTM)
-25.85
Beta
0.95
Day Range
558.00p - 585.00p
52 Week Range
232.50p570.00p585.00p
570.00p
Upcoming Events
OXB
NEUTRALOxford Biomedica Announces Holding Change
The biotechnology company has announced a change in shareholding, with Briarwood Chase Management LLC increasing its stake to 15.51%.
OXB
NEUTRALOxford Biomedica Announces Admission of New Shares
The biotechnology company has announced the admission of new ordinary shares to trading on the London Stock Exchange.
OXB
NEUTRALOxford Biomedica Announces PDMR Dealings
The biotechnology company has announced a PDMR dealing, with a non-executive director purchasing a block of shares.
OXB
NEUTRALOxford Biomedica Completes £60 Million Placing
The biotechnology company has raised £60 million through a share placing to fund strategic investments and expand its US commercial-scale capacity.
OXB
NEUTRALOxford Biomedica Announces £60 Million Equity Raise to Fund Global Expansion
The biotechnology company announces a £60 million equity raise to fund global expansion, including US manufacturing capacity growth. Details on the raise price and potential dilution for existing shareholders are unclear.
OXB
GOODOxford Biomedica Secures $125 Million Loan Facility from Oaktree
The biotechnology company has secured a new $125 million loan facility from Oaktree Capital Management to support its global operations and growth strategy.
OXB
VERY GOODOxford Biomedica Delivers Strong H1 2025 Performance, Reiterates Full Year Guidance
The biotechnology company reported strong first half results, with revenues up over 38% and a robust order book. The firm reiterated its full year guidance, signaling confidence in its performance.
OXB
NEUTRALOxford Biomedica Announces Director Appointment
The biotechnology company has announced the appointment of an independent non-executive director to its board.
OXB
NEUTRALOxford Biomedica Completes Acquisition of US Subsidiary
The biotechnology company has completed the acquisition of the remaining 10% stake in its US subsidiary, aligning with its global strategy and supporting growth in the viral vector manufacturing market.